Moderna and Merck Personalized mRNA Cancer Vaccine Succeeds in First-Ever Late-Stage Melanoma Trial

Moderna and Merck announced on August 19 that their jointly developed personalized mRNA cancer vaccine, intismeran, met both its primary and key secondary endpoints in a Phase 3 clinical trial involving 1,137 melanoma patients. The treatment reduced cancer recurrence and prevented the spread of disease to other parts of the body in patients whose tumors …